sub:assertion {
d:DB00458 dv:ddi-interactor-in dr:DB00458_DB00472 .
d:DB00472 dv:ddi-interactor-in dr:DB00458_DB00472 .
dr:DB00458_DB00472 dct:identifier "drugbank_resource:DB00458_DB00472" ;
dct:title "DDI between Imipramine and Fluoxetine - The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of imipramine if fluoxetine is initiated, discontinued or dose changed."@en ;
a dv:Drug-Drug-Interaction ;
rdfs:label "DDI between Imipramine and Fluoxetine - The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of imipramine if fluoxetine is initiated, discontinued or dose changed. [drugbank_resource:DB00458_DB00472]"@en .
}